AbbVie Inc

4AB

Company Profile

  • Business description

    AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

  • Contact

    1 North Waukegan Road
    North ChicagoIL60064-6400
    USA

    T: +1 847 932-7900

    E: [email protected]

    https://www.abbvie.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    55,000

Stocks News & Analysis

stocks

Acquisition a sign of weakness for overvalued ASX share

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
stocks

ASX opportunities after earnings season

Finding value in an expensive market.
stocks

3 global ‘buy the dip’ candidates with wide moats

Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,120.9034.100.38%
CAC 407,861.5236.280.46%
DAX 4023,766.7568.600.29%
Dow JONES (US)45,834.22273.78-0.59%
FTSE 1009,281.531.76-0.02%
HKSE26,405.9517.790.07%
NASDAQ22,141.1098.030.44%
Nikkei 22544,768.12395.620.89%
NZX 50 Index13,208.3119.59-0.15%
S&P 5006,584.293.18-0.05%
S&P/ASX 2008,853.0031.600.36%
SSE Composite Index3,860.5010.09-0.26%

Market Movers